MedTrace Logo

A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

NCT05160168 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2024-06-05

Study results available
· View outcomes & findings →

Summary

This study will assess the safety, efficacy, and pharmacokinetics of THE-630 in participants with advanced gastrointestinal stromal tumors (GIST).

Conditions

  • Gastrointestinal Stromal Tumors (GIST)
  • Neoplasms, Connective Tissue
  • Neoplasms, Connective and Soft Tissue
  • Neoplasms by Histologic Type
  • Neoplasms
  • Gastrointestinal Neoplasms
  • Digestive System Neoplasm
  • Digestive System Disease
  • Gastrointestinal Diseases

Interventions

DRUG

THE-630

Oral THE-630 administered once daily in a continuous regimen

Sponsors & Collaborators

  • Theseus Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Stew Kroll · Theseus Pharmaceuticals (a subsidiary of Concentra Biosciences)

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-03
Primary Completion
2024-02-02
Completion
2024-02-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05160168 on ClinicalTrials.gov